81 related articles for article (PubMed ID: 1563679)
1. [CA15-3 tumor marker in early detection of breast cancer].
Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
[TBL] [Abstract][Full Text] [Related]
2. [Evaluation of tumor marker CA15-3 in breast cancer].
Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of tumor markers in breast cancer].
Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
[TBL] [Abstract][Full Text] [Related]
4. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
[TBL] [Abstract][Full Text] [Related]
5. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
Suzuki S; Nihei M; Nomizu T; Watanabe T; Kimijima I; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):1019-26. PubMed ID: 2202768
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of tumor markers in breast cancer patients].
Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
[TBL] [Abstract][Full Text] [Related]
7. [Tumor marker: practical usage of tumor marker for recurrent breast cancer--our experience].
Yoshimoto M
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2277-83. PubMed ID: 2241194
[TBL] [Abstract][Full Text] [Related]
8. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
Barak V; Carlin D; Sulkes A; Treves A; Biran S
Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
[TBL] [Abstract][Full Text] [Related]
9. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
Kaneko Y; Imoto S; Kasakura S
Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
[TBL] [Abstract][Full Text] [Related]
10. The use of CA15.3 as a serum tumour marker in breast carcinoma.
Duncan JL; Price A; Rogers K
Eur J Surg Oncol; 1991 Feb; 17(1):16-9. PubMed ID: 1995353
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumour markers TAG 12 with CA 15-3 and MCA in breast cancer diagnosis.
Eskelinen M; Hippelainen M; Salmela E; Paajanen H; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(1):39-42. PubMed ID: 1567179
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
13. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
14. Relation between the method of detection of initial breast carcinoma and the method of detection of subsequent ipsilateral local recurrence and contralateral breast carcinoma.
Chen C; Orel SG; Harris EE; Hwang WT; Solin LJ
Cancer; 2003 Oct; 98(8):1596-602. PubMed ID: 14534874
[TBL] [Abstract][Full Text] [Related]
15. A prospective evaluation of CA15-3 in stage I carcinoma of the breast.
O'Hanlon DM; Kerin MJ; Kent PJ; Skehill R; Maher D; Grimes H; Given HF
J Am Coll Surg; 1995 Feb; 180(2):210-2. PubMed ID: 7850057
[TBL] [Abstract][Full Text] [Related]
16. Relative operating characteristic analysis and group modeling for tumor markers: comparison of CA 15.3, carcinoembryonic antigen, and mucin-like carcinoma-associated antigen in breast carcinoma.
Silver HK; Archibald BL; Ragaz J; Coldman AJ
Cancer Res; 1991 Apr; 51(7):1904-9. PubMed ID: 2004374
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
[TBL] [Abstract][Full Text] [Related]
18. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
[TBL] [Abstract][Full Text] [Related]
19. [A study of the clinical usefulness of the CA15-3 radioimmunoassay kit].
Abe Y; Odagiri E; Jibiki K; Demura R; Demura H
Gan No Rinsho; 1988 Oct; 34(12):1672-6. PubMed ID: 3193612
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
